Bridge Biotherapeutics, Inc.
Taiguang (Jimmy) Jin is currently the VP and Head of Discovery Biology at Bridge Biotherapeutics, Inc. Prior to this, Taiguang (Jimmy) was the founder and CEO of Aspace Pharmaceuticals Ltd, where Taiguang (Jimmy) was responsible for establishing R&D pipelines through partnerships with biotech companies. Taiguang (Jimmy) has a strong background in translational medicine, having worked as the Director at the Therapeutic Strategy Unit, Asia Pacific R&D at Sanofi. With experience at Roche as the Deputy Head of Discovery Oncology, Taiguang (Jimmy) has expertise in project management, portfolio management, and external collaboration. Taiguang (Jimmy) holds a Ph.D in Molecular Biology from Kobe University and an M.D in Mental Health from Peking University School of Medicine.
This person is not in any offices
Bridge Biotherapeutics, Inc.
Bridge Biotherapeutics, Inc. is a virtually-operated, venture-backed clinical stage global biotech company, headquartered in Seongnam, Korea with its subsidiary at JLABS@TMC, engaged in the development of novel therapeutics, focusing on therapeutic areas of high unmet medical needs, such as ulcerative colitis, fibrotic diseases, and cancers.